aTYR PHARMA INC — Director's Dealing 2026

Jan 9, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (ATYR)
CIK: 0001339970
Period of Report: 2026-01-09

Reporting Person: DENYES NANCY (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-09	Employee Stock Options (right to buy)	$0.7127	A	412500	Acquired	2036-01-09	Common Stock (412500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	31555	Direct

Footnotes

F1: Includes 2,500 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the Company's 2015 Employee Purchase Plan.

F2: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 9, 2026, such that this option will be fully exercisable on January 9, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.